<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03522675</url>
  </required_header>
  <id_info>
    <org_study_id>CL-18002</org_study_id>
    <nct_id>NCT03522675</nct_id>
  </id_info>
  <brief_title>NeoMatriX Wound Matrix Collagen Dressing Skin Prick Test</brief_title>
  <official_title>Skin Prick Test in Healthy Volunteers of Any Sex, to Investigate the Potential Allergy to NeoMatriXTM Wound Matrix</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NeXtGen Biologics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>State University of New York at Buffalo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>NeXtGen Biologics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to investigate the potential of NeoMatriXTM Wound Matrix to
      cause an allergic response to healthy volunteers using a skin prick test.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Using a minimally invasive skin prick test, the test material, positive control, and negative
      control are applied to the forearm using a prick test. The test area is observed after 15
      minutes, 6 hours, and again at 1-2 days after the initial prick test. The skin will be
      examined for a reaction such as a wheal and/or a flare, a flare alone is not clinically
      significant.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 11, 2018</start_date>
  <completion_date type="Actual">April 28, 2018</completion_date>
  <primary_completion_date type="Actual">April 26, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Wheal Formation</measure>
    <time_frame>15 minutes</time_frame>
    <description>Wheal formation is defined as a raised, pale, itchy formation (allergic reaction) on the skin's surface. A positive (+) allergic response would be indicated by the NeoMatriXTM Wound Matrix producing a wheal &gt;3 mm of the positive control (histamine).</description>
  </primary_outcome>
  <other_outcome>
    <measure>Wheal Formation</measure>
    <time_frame>6 hrs</time_frame>
    <description>Wheal formation is defined as a raised, pale, itchy formation (allergic reaction) on the skin's surface. A positive (+) allergic response would be indicated by the NeoMatriXTM Wound Matrix producing a wheal &gt;3 mm of the positive control (histamine).</description>
  </other_outcome>
  <other_outcome>
    <measure>Wheal Formation</measure>
    <time_frame>2 days</time_frame>
    <description>Wheal formation is defined as a raised, pale, itchy formation (allergic reaction) on the skin's surface. A positive (+) allergic response would be indicated by the NeoMatriXTM Wound Matrix producing a wheal &gt;3 mm of the positive control (histamine).</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Allergy Skin</condition>
  <condition>Allergy</condition>
  <condition>Dermatitis, Allergic Contact</condition>
  <arm_group>
    <arm_group_label>NeoMatriX and Two Comparators</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>NeoMatriX Wound Matrix Collagen Dressing 8mm disc Histamine positive control (0.1mL) Normal saline negative control (0.1mL)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NeoMatriX Wound MatriX Collagen Dressing</intervention_name>
    <description>Collagen wound dressing</description>
    <arm_group_label>NeoMatriX and Two Comparators</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers aged at least 18 years.

          -  Completed written informed consent and receive a copy of their executed ICF.

          -  Volunteers must be capable of understanding and following directions in English.

        Exclusion Criteria:

          -  Pregnancy or lactation;

          -  Inadequate or non-existent contraception (women of child bearing potential only);

          -  A current skin disease;

          -  Heavy alcohol consumption;

          -  Current use or history of repeated use of recreational drugs;

          -  Recent illness prior to test;

          -  Significant past medical history of diseases to potentially effect study results;

          -  Current treatment of allergy;

          -  A history of multiple drug hypersensitivity;

          -  Concurrent medication likely to affect the response to the test articles or confuse
             the results of the study;

          -  Known sensitivity to the test articles;

          -  Participation in a repeat insult patch test (RIPT), skin prick test (SPT) or follow-up
             work within the last month;

          -  Sensitization or questionable sensitization in a skin test;

          -  Recent immunization.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University at Buffalo Clinical and Translational Research Center</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>April 19, 2018</study_first_submitted>
  <study_first_submitted_qc>April 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2018</study_first_posted>
  <results_first_submitted>April 18, 2019</results_first_submitted>
  <results_first_submitted_qc>May 30, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 31, 2019</results_first_posted>
  <last_update_submitted>May 30, 2019</last_update_submitted>
  <last_update_submitted_qc>May 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Allergic Contact</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Not yet determined</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 10, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/75/NCT03522675/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>NeoMatriX and Two Comparators</title>
          <description>NeoMatriX Wound Matrix Collagen Dressing 8mm disc Histamine positive control (0.1mL) Normal saline negative control (0.1mL)
NeoMatriX Wound MatriX Collagen Dressing: Collagen wound dressing</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Screen fail</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-reactive to histamine</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>NeoMatriX and Two Comparators</title>
          <description>NeoMatriX Wound Matrix Collagen Dressing 8mm disc Histamine positive control (0.1mL) Normal saline negative control (0.1mL)
NeoMatriX Wound MatriX Collagen Dressing: Collagen wound dressing</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.35" lower_limit="21" upper_limit="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Wheal Formation</title>
        <description>Wheal formation is defined as a raised, pale, itchy formation (allergic reaction) on the skin's surface. A positive (+) allergic response would be indicated by the NeoMatriXTM Wound Matrix producing a wheal &gt;3 mm of the positive control (histamine).</description>
        <time_frame>15 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NeoMatriX Alone</title>
            <description>NeoMatriX Wound Matrix Collagen Dressing 8mm disc
NeoMatriX Wound MatriX Collagen Dressing: Collagen wound dressing</description>
          </group>
          <group group_id="O2">
            <title>Positive Control</title>
            <description>Histamine positive control (0.1mL)</description>
          </group>
          <group group_id="O3">
            <title>Negative Control</title>
            <description>Normal saline negative control (0.1mL)</description>
          </group>
        </group_list>
        <measure>
          <title>Wheal Formation</title>
          <description>Wheal formation is defined as a raised, pale, itchy formation (allergic reaction) on the skin's surface. A positive (+) allergic response would be indicated by the NeoMatriXTM Wound Matrix producing a wheal &gt;3 mm of the positive control (histamine).</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".85" lower_limit="0" upper_limit="3.5"/>
                    <measurement group_id="O2" value="6.68" lower_limit="4.5" upper_limit="11"/>
                    <measurement group_id="O3" value=".2" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Wheal Formation</title>
        <description>Wheal formation is defined as a raised, pale, itchy formation (allergic reaction) on the skin's surface. A positive (+) allergic response would be indicated by the NeoMatriXTM Wound Matrix producing a wheal &gt;3 mm of the positive control (histamine).</description>
        <time_frame>6 hrs</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NeoMatriX Alone</title>
            <description>NeoMatriX Wound Matrix Collagen Dressing 8mm disc
NeoMatriX Wound MatriX Collagen Dressing: Collagen wound dressing</description>
          </group>
          <group group_id="O2">
            <title>Positive Control</title>
            <description>Histamine positive control (0.1mL)</description>
          </group>
          <group group_id="O3">
            <title>Negative Control</title>
            <description>Normal saline negative control (0.1mL)</description>
          </group>
        </group_list>
        <measure>
          <title>Wheal Formation</title>
          <description>Wheal formation is defined as a raised, pale, itchy formation (allergic reaction) on the skin's surface. A positive (+) allergic response would be indicated by the NeoMatriXTM Wound Matrix producing a wheal &gt;3 mm of the positive control (histamine).</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0.1" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Wheal Formation</title>
        <description>Wheal formation is defined as a raised, pale, itchy formation (allergic reaction) on the skin's surface. A positive (+) allergic response would be indicated by the NeoMatriXTM Wound Matrix producing a wheal &gt;3 mm of the positive control (histamine).</description>
        <time_frame>2 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NeoMatriX Alone</title>
            <description>NeoMatriX Wound Matrix Collagen Dressing 8mm disc
NeoMatriX Wound MatriX Collagen Dressing: Collagen wound dressing</description>
          </group>
          <group group_id="O2">
            <title>Positive Control</title>
            <description>Histamine positive control (0.1mL)</description>
          </group>
          <group group_id="O3">
            <title>Negative Control</title>
            <description>Normal saline negative control (0.1mL)</description>
          </group>
        </group_list>
        <measure>
          <title>Wheal Formation</title>
          <description>Wheal formation is defined as a raised, pale, itchy formation (allergic reaction) on the skin's surface. A positive (+) allergic response would be indicated by the NeoMatriXTM Wound Matrix producing a wheal &gt;3 mm of the positive control (histamine).</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>NeoMatriX Alone</title>
          <description>NeoMatriX Wound Matrix Collagen Dressing 8mm disc
NeoMatriX Wound MatriX Collagen Dressing: Collagen wound dressing</description>
        </group>
        <group group_id="E2">
          <title>Histamine + NeoMatriX</title>
          <description>NeoMatriX Wound Matrix Collagen Dressing 8mm disc Histamine positive control (0.1mL)</description>
        </group>
        <group group_id="E3">
          <title>Saline + NeoMatriX</title>
          <description>NeoMatriX Wound Matrix Collagen Dressing 8mm disc
Normal saline negative control (0.1mL)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dayna Healy</name_or_title>
      <organization>NeXtGen Biologics, Inc</organization>
      <phone>352-215-9961</phone>
      <email>Dhealy@nextgenbiologics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

